Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Bethesda, MD 20852, USA.
Breast Cancer Res Treat. 2012 Feb;131(3):1021-7. doi: 10.1007/s10549-011-1820-8. Epub 2011 Oct 21.
Radiation exposure, particularly at a young age, is an established cause of breast cancer. It is not known whether radiation-related breast cancer risk varies by molecular subtype. We characterized the relative risk (RR) of contralateral breast cancer (CBC) related to radiotherapy by histology and estrogen receptor (ER) status of the CBC in five-year survivors in the Surveillance, Epidemiology, and End Results database using Poisson regression models adjusted for attained age and calendar year, age at and year of treatment, ER status of the first breast cancer, and disease stage. 205,316 female breast cancer survivors were followed for an average of 10 years from 1973 until 2007, during which time 6924 women developed a subsequent primary invasive breast cancer in the contralateral breast. The overall RR (and 95% confidence interval (CI)) of radiotherapy-related CBC was 1.11 (1.05-1.16). There was no heterogeneity in risk according to histology of the CBC (P > 0.50) for all ages or young age at exposure, but case numbers were small for subtypes other than ductal and lobular carcinomas. Information on ER status was available from 1990 onwards for 3546 CBC cases, of which 2597 (73%) were ER+ and 949 (27%) were ER-. The RRs were 1.10 (1.02-1.19) for ER+ CBC and 1.19 (1.04-1.35) for ER- CBC (P (difference) = 0.33). Among women treated age <35 years, radiation-related risk of CBC was non-significantly elevated for ER- (RR = 1.38, 95% CI: 0.96-1.97) but not for ER+ tumors (RR = 0.80, 95% CI: 0.47-1.35) (P (difference) = 0.09). We did not find clear evidence that radiation-related risk varies by histology or ER status, but our findings, which were the first to examine this question, were suggestive of possible differences by ER status that may merit further investigation.
辐射暴露,特别是在年轻时,是乳腺癌的一个已确定的病因。目前尚不清楚放射相关乳腺癌风险是否因分子亚型而异。我们使用泊松回归模型,根据年龄和日历时间、首次乳腺癌的治疗年龄和年份、雌激素受体状态和疾病分期,对监测、流行病学和最终结果数据库中五年生存者的放射治疗相关对侧乳腺癌(CBC)的相对风险(RR)进行了特征描述。从 1973 年到 2007 年,对 205316 名女性乳腺癌幸存者进行了平均 10 年的随访,在此期间,6924 名女性在对侧乳房发生了后续原发性浸润性乳腺癌。放疗相关 CBC 的总体 RR(95%置信区间(CI))为 1.11(1.05-1.16)。无论年龄大小或暴露时年龄大小如何,CBC 组织学的风险均无差异(P>0.50),但除导管癌和小叶癌以外的亚型病例数较少。从 1990 年开始,有 3546 例 CBC 病例可获得雌激素受体状态信息,其中 2597 例(73%)为雌激素受体阳性,949 例(27%)为雌激素受体阴性。雌激素受体阳性 CBC 的 RR 为 1.10(1.02-1.19),雌激素受体阴性 CBC 的 RR 为 1.19(1.04-1.35)(P(差异)=0.33)。在年龄<35 岁的女性中,CBC 的放射相关风险对于雌激素受体阴性(RR=1.38,95%CI:0.96-1.97)而非雌激素受体阳性肿瘤(RR=0.80,95%CI:0.47-1.35)升高(P(差异)=0.09)。我们没有发现明确的证据表明放射相关风险因组织学或雌激素受体状态而异,但我们的发现首次对此问题进行了检验,表明雌激素受体状态可能存在差异,值得进一步研究。